BioCentury
ARTICLE | Clinical News

Merck's letermovir passes Phase III CMV test

October 19, 2016 7:00 AM UTC

Merck & Co. Inc. (NYSE:MRK) said letermovir ( MK-8228) met the primary endpoint of a Phase III study to prevent cytomegalovirus infection in CMV-seropositive adults who have received a hematopoietic stem cell transplant. Spokesperson Pamela Eisele said the company is planning regulatory submissions of the candidate, but declined to disclose a timeline.

The study evaluated the percentage of patients with clinically significant CMV infection through 24 weeks after transplant in patients receiving once-daily letermovir or placebo. Merck said it will present the results at an upcoming medical meeting. ...